CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 891,164	$ 5,262,752
Total cost of revenues	660,067	2,885,069
Gross profit	231,097	2,377,683
Operating expenses:
Selling, general and administrative	3,084,348	2,625,357
Research and development	935,815	971,304
Total operating expenses	4,020,163	3,596,661
LOSS FROM OPERATIONS	(3,789,066)	(1,218,978)
Interest income	33,323	3,686
Unrealized gain (loss) on change in fair value of warrants classified as a liability	2,639,000	(2,637,800)
Other (expense) income, net	(13,538)	8,846
Loss before provision for income taxes	(1,130,281)	(3,844,246)
NET LOSS	(1,130,281)	(3,844,246)
Less: Net loss attributable to noncontrolling interest	25,181	874
NET LOSS attributable to Applied DNA Sciences, Inc.	(1,105,100)	(3,843,372)
Deemed dividend related to warrant modifications	(77,757)
NET LOSS attributable to common stockholders	$ (1,182,857)	$ (3,843,372)
Net loss per share attributable to common stockholders - basic	$ (0.09)	$ (0.30)
Net loss per share attributable to common stockholders - diluted	$ (0.09)	$ (0.30)
Weighted average shares outstanding - basic	13,673,433	12,908,520
Weighted average shares outstanding - diluted	13,673,433	12,908,520
Product revenues
Revenues
Total revenues	$ 307,317	$ 516,396
Total cost of revenues	282,545	365,378
Service revenues
Revenues
Total revenues	247,147	232,061
Clinical laboratory service revenues
Revenues
Total revenues	336,700	4,514,295
Total cost of revenues	$ 377,522	$ 2,519,691